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ABSTRACT 
Hemodialysis patient with chronic HCV infection, who was started on monotherapy with interferon. Quali-
tative HCV RNA remained positive at 12 weeks of treatment; ribavirin was associated. HCV RNA was nega-
tive at week 24 and treatment was extended to 72 weeks. HCV RNA negative six months after treatment. 
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INTRODUCTION
The prevalence of hepatitis C virus (HCV) 
infection ranges from 1% to 3% in general 
population,1 but it is higher in hemodialysis 
(HD) patients, ranging from 3% to 23%.1 This 
difference can be related to the fact that patients 
on HD have risk factors for acquisition of HCV, 
such as receipt of blood transfusions and use of 
illicit intravenous drug, and may also acquire 
bloodborne infections as a result of healthcare-
associated transmission in HD units. Several 
mechanisms have been implicated in HCV 
transmission among HD patients, such as dia-
lyzer reuse, contamination of hands of staff 
members, or items shared among patients.1
HCV infection increases mortality in HD pa-
tients and in renal transplant recipients (RTR).2,3 
Cirrhosis and hepatocellular carcinoma (HCC), 
major complications of HCV-associated chronic 
liver disease, have been implicated as causes of 
increased mortality in HD patients with HCV 
infection.2,4 A study among HD patients showed 
that HCC accounted for 5.5% of all deaths in the 
group with HCV infection compared with 0% in 
the group without HCV infection.5 In addition, 
cirrhosis was documented in 8.8% and 0.4% of 
deceased patients with and without HCV infec-
tion, respectively (p < 0.001).5 
Reduced survival in RTRs with HCV is at-
tributable to advanced liver disease and sepsis.6 
Both liver disease and sepsis in RTRs with HCV 
are likely to be direct consequences of cirrhosis. 
In a case-control study, cirrhosis was the most 
signifi cant independent predictor of death after 
renal transplantation.7 Despite the increase of 
liver disease and sepsis in RTRs, renal trans-
plantation improves overall survival in non-
cirrhotic patients with HCV in HD.8 
The presence of cirrhosis in HD patients 
with HCV infection is considered a relative 
contraindication for renal transplantation due 
to possible progression of liver disease.6 Com-
bined transplantation (liver/kidney transplan-
tation) is recommended in renal transplanta-
tion candidates with decompensate cirrhosis. It 
is often recommended that HD patients with 
compensated cirrhosis whose liver function is 
too well compensated to require liver trans-
plantation remain on dialysis.6 
Because sustained HCV suppression pre-
vents progression of liver disease and HCV 
therapy with interferon (IFN) is not recom-
mended after renal transplantation, antiviral 
therapy should be considered for patients in 
HD with HCV infection prior to transplant.6 
Patients with compensated hepatitis C cirrho-
sis who achieve sustained viral response (SVR), 
i.e., negative HCV RNA six months after treat-
ment, may become suitable candidates for iso-
lated renal transplantation.6 This emphasizes 
the potential benefi t of HCV antiviral treat-
ment. However, at present, therapy for hepatitis 
C in HD patients is diffi cult, especially because 
of potential adverse effects of treatment and 
presence of comorbidities in these patients. 
In this report, we present a HD patient with 
chronic HCV infection and cirrhosis treated 
with IFN monotherapy for 16 weeks, and IFN 
plus ribavirin (RBV) for additional 56 weeks. 
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CASE REPORT
A 44-year-old man in HD and with serum anti-HCV anti-
bodies detected by enzyme immunoassay (Abbott AxSYM 
AntiHCV 3.0, Abbott Laboratories, Wiesbaden, Germany) 
was referred to the Viral Hepatitis Study Group of Clinics 
Hospital, State University of Campinas for HCV infection 
evaluation and follow-up. Patient reported use of illicit drugs 
20 years before that time, has been in HD for six months, 
and denied current alcohol abuse. The chronic renal failure 
was of unknown etiology. Patient used erythropoetin (EPO) 
10,000 UI once a week. Serum HCV RNA was detected by 
qualitative PCR (Cobas Amplicor HCV Test v2.0, Roche 
Molecular Diagnostic Systems, Branchburg, USA), and 
HCV genotype 1 was identifi ed. Baseline laboratory fi nd-
ings are show in Table 1. Of note, thyroid function tests and 
protein electrophoresis did not reveal any abnormality. HIV 
and hepatitis B serologies were both negative.
Patient’s physical exam was unremarkable with a weight 
of 80 kg and a body mass index (BMI) of 27.5 kg/m2. Ab-
domen ultrasound showed signals of liver cirrhosis and 
splenomegaly; digestive endoscopic did not reveal esophageal 
varices. Monotherapy treatment with IFN-α 3 million units 
subcutaneously, three times a week was initiated. Qualitative 
HCV RNA remained positive at weeks 4 and 12 of treatment 
(Figure 1). Oral RBV was associated with IFN at week 16 
of treatment, at a dose of 500 mg per day. HCV RNA was 
negative at week 24. At week 30, RBV dose was increase to 
750 mg/day. By week 72, end of HCV treatment, HCV RNA 
was negative. Patient had negative HCV RNA when tested 
six months after treatment, which characterizes SVR.
Patient tolerated treatment well and did not present with 
signifi cant side effects. During the fi rst month of therapy, he 
had ﬂ u-like symptoms managed with paracetamol. Patient 
did not experience a decrease in serum hemoglobin (Hb) 
level (Figure 1) during treatment, and it was not necessary to 
increase EPO dose already in use in HCV treatment. 
 
Table 1. Baseline laboratory findings of patient with chronic hepatitis C and on hemodialysis
         Exam Patient result  Reference value
Leukocytes (cells/mm3) 6,800 4,000–10,000
Platelets (cells/mm3) 223,000 150,000–400,000
Hemoglobin (g/dL) 13.10 14.0–18.0
Total bilirrubin (mg/dL) 0.8 < 1.0
Glucose (mg/dL) 89 70–100
Alanine aminotransferase (U/L) 84 < 40
Aspartate aminotransferase (U/L) 42 < 37
Alkaline phosphatase (U/L) 67 40–129
Glutamyltransferase (U/L) 47 9–40
Albumin (g/dL) 4.8 3.4–4.8
Alfa-feto protein (mg/mL) 1.78 < 7
RNI 1.02 1.0
Creatine  10.75 < 1.2
Urea nitrogen 150 10–50
Serum cryoglobulins Positive Negative
Rheumatic factor (UI/mL) < 8.5 < 15
Figure 1: Alanine aminotransferase (ALT) and hemoglobin 
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DISCUSSION
The standard treatment for patients with chronic hepatitis 
C genotype 1 infection is pegylated interferon alfa (PEG-
IFN) therapy in combination with RBV for 48 weeks and 
24 weeks for patients with genotype 3 infection. In non-HD 
patients, this combination achieved SVR in 50% to 60% of 
patients.1 There is no current optimal therapy for hepatitis C 
in HD patients. The combination of PEG-IFN and RBV has 
not been studied extensively in HD patients, as most studies 
have focused on monotherapy with IFN. Two meta-analyses 
reported SVR rates of 33% and 37% in HD patients treated 
with IFN as monoteraphy.10,11 These rates are signifi cantly 
greater than the SVR rates observed in previously published 
studies, 10% to 20%, among non-HD patients treated with 
IFN monoteraphy.1 These increased response rates may be 
partially explained by an increased half-life of IFN in HD 
patients, resulting in greater plasma levels and consequent 
increase in effi cacy and also in the incidence of side effects. 
In HD patients, SVR rates in three studies of PEG-IFN 
monotherapy were similar (37%) to those for IFN mono-
therapy, but SVR rates increased to 97% and 44% in two 
studies using PEG-IFN and RBV.1 In this report, we de-
scribed a patient in HD with HCV chronic infection treated 
with IFN-α monoteraphy for 16 weeks and then with IFN-α 
and RBV for additional 56 weeks. HCV RNA become nega-
tive only after RBV was initiated.
Clinicians are usually reluctant to use RBV in HD pa-
tients because only a small part of the drug is eliminated 
during HD sessions and side effects include a dose-depend-
ent hemolysis, which may be even more severe in chroni-
cally anemic HD patients.12 In addition, a lack of knowledge 
about adequate RBV dosing and presence of other comor-
bidities (e.g., cardiac ischemia) has further discouraged the 
use of RBV in HD patients. However, studies have evaluated 
combination therapy of either PEG-IFN or IFN-α plus RBV 
in patients in maintenance HD.13,14 In one study, SVR rate in 
HD patients treated with IFN-α plus RBV was 83.3%, and 
the most frequent side effect of RBV was a dose-dependent 
hemolysis, which required treatment discontinuation in 
some patients.14 This concentration-monitored safety study 
indicated that it was possible to use combination therapy, 
IFN-α plus RBV, in HD patients. However, some precau-
tions were suggested for RBV use in this setting, including 
close monitoring of Hb levels, reduced doses of RBV, start 
using EPO or, in those patients already using EPO, increase 
its dosing either increasing doses of EPO in patients already 
in use or its initiation others.15 Transfusions and RBV dis-
continuation may be necessary to manage RBV-induced 
anemia in some patients.
In our report, the initial RBV dose could be considered 
low for an 85 kg patient. The standard RBV dose for a non-
HD patient infected with genotype 1 is 15 mg/kg, equivalent 
to 1,200 mg in this patient. Patient tolerated treatment well 
and did not develop RBV-induced anemia. So, it was not 
necessary to increase his EPO dose. The small sample size 
of previous studies in HD and chronic hepatitis C patients 
hampers defi nitive conclusions about optimal therapy, but 
encouraging results in terms of effi cacy and safety have been 
reported.4,14 Randomized trials with large numbers of pa-
tients are necessary to investigate optimal combination ther-
apy and management of side effects among HD patients. 
There is a lack of comprehensive information on HCV-
related cirrhosis in patients in HD, as studies are limited to 
a few case reports. Standard IFN-α monotherapy in three 
HD HCV-infected patients with cirrhosis showed revers-
ibility of cirrhosis by biopsy in two of them.16 Our patient 
had evidence of cirrhosis on ultrasound and we decided not 
to perform liver biopsy before and after antiviral treatment, 
but SVR after treatment as seen in this patient is usually as-
sociated with improved liver histology.17 
Virological response to HCV treatment in non-HD pa-
tients is inﬂ uenced by different host and virus factors. Host 
factors associated with a reduced virological response to 
PEG-IFN and RBV combination therapy are older age, male 
gender, African-American ethnicity, elevated BMI, advanced 
fi brosis or cirrhosis, and liver steatosis.18 The most impor-
tant viral factor for prediction of virological response is the 
HCV genotype. HCV genotype 2- or 3-infected patients 
generally have higher SVR rates than genotype 1-infected 
patients. In addition, a low baseline viral load is also associ-
ated with increased rates of virological response.17 Similar 
to non-HD patients, greater SVR rates were observed in HD 
patients with non-HCV genotype 1 infections, without cir-
rhosis or bridging fi brosis, and low mean pretreatment HCV 
RNA levels.1 
We noticed that our patient had some factors, such as 
genotype 1 infection, male gender, elevated BMI, and cir-
rhosis, that have been shown to be predictors of decreased 
response to IFN-α and RBV therapy.18 For non-HD pa-
tients, a slow virological response to HCV treatment can be 
defi ned as patients who become HCV RNA negative only 
at week 24.
As shown by previous studies, prolongation of therapy 
from 48 to 72 weeks may be necessary in patients with slow 
virological response.19 Extending combination therapy from 
48 to 72 weeks led to an increase of SVR rates from 17% to 
29% among patients with detectable HCV RNA at week 12 
who became HCV RNA negative only by week 24.19 Because 
our patient was a slow virological responder, HCV RNA 
negativation at week 24, we decided to extend his treatment 
to 72 weeks, and he attained SVR. At the present, no studies 
evaluating extended HCV therapy in HD patients are availa-
ble; therefore, further studies are necessary to determine the 
appropriate duration of HCV treatment in HD patients. 
There is little information on optimal treatment of hepa-
titis C among HD patients. The decision to initiate IFN and 
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RBV therapy in such patients should be based on histologi-
cal severity of liver disease, presence of comorbidities, and 
expected tolerance of side effects. In addition, clinicians 
should carefully monitor the patient during treatment and 
make necessary adjustments to reach desired outcomes and 
minimize side effects. By doing so, it may be possible to 
achieve high rates of SVR with the already available treat-
ment options. 
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